NCT03836599 - A Study to Assess the Safety and Pharmacokinetics of Verinurad and Allopurinol in Asian and Chinese Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 16, 2019

Primary Completion Date

April 26, 2019

Study Completion Date

April 26, 2019

Conditions

Chronic Kidney Disease

Interventions

DRUG

Verinurad

Participants will receive verinurad 24 mg in cohort 1 and 12 mg in cohort 2 once daily.

DRUG

Allopurinol

Participants will receive allopurinol 300 mg once daily.

DRUG

Placebo

During Run-in Period, participants in cohort 1 will receive placebo matching allopurinol capsule once daily from Day -7 to Day -1. During treatment period, participants in cohort 1 will receive placebo matching allopurinol capsule and placebo matching verinurad capsule once daily from Day 1 to Day 7.

Trial Locations (1)

91206

Research Site, Glendale